参展商

Neonatal jaundice affects up to 85% of full-term newborns and remains one of the most common health challenges in early life. Traditional hospital-based monitoring methods are often complex,expensive, and inaccessible for home use or grassroots clinics.Bilimonitor redefines jaundice management with a clinically validated, non-invasive, and easy-to-use solution for both parents and healthcare providers. It enables at-home, clinical -grade monitoring andsupports reliable screening in primary care settings.Since launch, Bilimonitor has supported the healthy growth of over 250,000 newborns and formed strong partnerships with 200+ hospitals. Its consumer version has achieved over 200,000 units sold across leading platforms like JD.com, earning widespread trust and continued market momentum.With FDA Class II clearance and Southeast Asia registrations in progress, Bilimonitor is accelerating its global rollout to meet growing demand for safer, more accessible jaundice care solutionsBilimonitor BJM-20Jaundice MeterLeveraging proprietary optoelectronic technology, we have redefined neonatal jaundice screening—achieving unprecedented accuracy and cost-efficiency.Medical-grade jaundice monitor, specifically optimized for home use. Enables convenient and continuous at-home monitoring while supporting remote doctor-patient follow-up, creating an efficient bridge home and clinic.

Modoo has emerged as one of the most trusted and innovative brands in remote fetal monitoring. As the world’s first and only passive, non-ultrasound fetal monitor, Modoo is revolutionizing prenatal care by enabling continuous, at-home fetal health tracking—without ultrasound, radiation, or the need for ultrasound gel.Modoo delivers clinical-grade insights by accurately monitoring fetal movement (FM), fetal heart rate (FHR), and uterine contractions. This allows for real-time risk detection and proactive intervention—capabilities previously only available in hospital settings. Integrated with the Modoo App, the system empowers families to effortlessly track fetal health and seamlessly share data with healthcare providers,bridging the gap between hospital-grade diagnostics and everyday maternal care.As the world's first non-ultrasound, intelligent fetal monitoring device, Modoo has already served over 300,000 families, contributing to the successful rescue of more than 550 newborns from critical conditions.Modoo’s adoption continues to scale rapidly. It is now in use at over 200 leading hospitals across Asia,including National University Hospital (Singapore), American-Sino Women’s &amp; Children’s Hospital, andShenzhen Union Hospital. With a hybrid B2B2C and DTC go-to-market strategy, Modoo is uniquely positioned to meet the demands of both healthcare institutions and expectant families, delivering professional-grade diagnostics with the convenience and accessibility of home care.As we expand internationally and move into predictive AI-powered capabilities, Modoo is not only redefining prenatal monitoring—it is setting a new global standard for maternal and fetal health. Modoo Smart Passive Fetal MonitorThe world’s smallest and first passive smart fetus monitoring device. Served 200K newborns with over 10M tests conducted.Modoo Pro Smart Fetal MonitorPassive fetal monitor with dual-probe sensors,enabling simultaneous monitoring of fetal movement, heart rate, and contractions.

E3A Healthcare proudly introduces Nora, our groundbreaking neuromodulation-based therapeutic device specifically developed for the treatment of endometriosis—a chronic condition impacting approximately 15% (300M) of women worldwide, characterized by severe chronic pain, infertility, and significant healthcare costs. Current treatments lack effectiveness, often relying heavily on invasive procedures or long-term medication use without fully addressing disease progression.Nora represents a significant advancement, providing a first-in-class, non-invasive, drug-free approach that effectively manages both pain relief and disease progression. Utilizing proprietary vagus nerve stimulation technology, Nora precisely targets neurological pathways associated with pain and inflammation, delivering effective symptom relief while potentially slowing disease progression. Nora's innovative approach holds tremendous potential for improving patient quality of life, reducing healthcare expenses, and providing substantial cost savings compared to conventional treatments, particularly within major healthcare markets such as the US and EU. Phase I Animal Study Successful &amp; PublishedOur neuromodulation therapy system has shown significant efficacy in both pain relief and lesion suppression in preclinical models of endometriosis.The underlying mechanisms—focusing on protein receptors and neural pathways involved in endometrial fibrosis—have been rigorously studied and published in top peer-reviewed journals include Nature Scientific Reports, and the Journal of Reproductive Biology.Phase II Human Pilot Study CompletedBuilding on the success of our animal studies, we have completed a human pilot study that further validated the efficacy of our technology intreating endometriosis and adenomyosis, demonstrating strong potential for clinical application.

展会概览

参展商名单

产品目录

展览厅切面图

成功故事

展会场刊 2025

重要公布

展会资讯

申请展位

参展费用及形式

广告服务

中小企业市场推广基金

资讯中心

参展资讯

网上预先登记

电子通讯

香港贸发局商贸平台APP及e-Badge

贸发网采购

访客规则及法规

请小心处理由第三者提供之推广优惠

E+ Premier Club

参观资讯

新闻稿

照片廊

展览视频

社交媒体/网络动态

新闻中心

合作媒体

传媒资讯

活动

香港的旅游签证和入境规例

办理中国内地入境签证及安排行程

特惠酒店

特惠机票

香港机场管理局提供专属优惠

香港跨境现金管制措施

前往会场

Information for Muslim Visitors

畅游香港

恶劣天气的安排

访港资讯

查询

常见问题

贸发局活动

研讨会及论坛

社交媒体/网络动态 - 2017

国泰航空机票优惠

照片廊 2023

参展商接待买家须知

社交媒体/网络动态 - 2016

社交媒体/网络动态 - 2019

免修订展览安全政策

社交媒体/网络动态 - 2021

提防有关信用卡终端机租赁服务

成功故事 2022

展会亮点

Homepage

绿色小贴士

通告

联系我们

亚洲区主要电子展览会

与会人士快速过关安排

穿梭巴士

卫生措施及健康资讯

参展商手册

额外设施及服务申请表格

重要日期清单

Virtual Booths

展览活动施工场地安全守则

成功故事 2023

照片廊 2022

成功故事 2024

Information for Muslim Visitors (只提供英文版本)

照片廊 2024